Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the ...

Learn about the executive team and board of directors at Myriad Genetics Inc (MYGN:XNAS) and review their bios and compensation over the latest fiscal years.

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved ...

G enetic testing company Myriad Genetics, the defendant in a landmark Supreme Court case over gene patents, is back in the spotlight — this time, for withholding genetic data from patients ...

Myriad Genetics, in its latest investor presentation, provided a breakdown of its major products' total addressable markets. It also projected a penetration level by 2020 in each market.

Myriad Genetics disparages its competitors for alleged mistakes in interpreting BRCA gene tests, but STAT found the company's claims were overstated.

Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing. The biotech company, the subject of a 2013 Supreme Court ruling that genes cannot be patented, said it was giving up trying to ...

Myriad Genetics beat analysts’ revenue expectations by 1.3% last quarter, reporting revenues of $213.3 million, up 11.2% year on year. It was a very strong quarter for the company, ...

Genetic tests like one offered by Myriad Genetics claim to analyze a patient's DNA and point them to the best depression drug for them. Myriad's test is called GeneSight and costs $2,000.

Personalized medicine has become one of the hottest areas of focus in healthcare. So you'd think that a company that touts itself as "the global.